文献速递糖尿病性腺与生殖内分泌

糖尿病妊娠技术路线图:2023年Norbert Freinkel奖讲座

A Diabetes Pregnancy Technology Roadmap: The 2023 Norbert Freinkel Award Lecture.
PubMed 文献 · Diabetes Care · 2024-01-01

该讲座回顾Norbert Freinkel关于1型糖尿病(T1D)妊娠期需更积极外源性胰岛素治疗的观点,结合连续葡萄糖监测(CGM)与混合闭环(HCL)胰岛素输注系统的进展,指出CGM虽获国际推荐但仅35%受试者在妊娠35周达到妊娠血糖目标,HCL(CamAPS FX系统)与TIRp提高10.5%相关。

要点

  • CONCEPTT试验促使国际推荐为所有T1D孕妇提供CGM以帮助达到妊娠血糖目标并改善新生儿结局。
  • 尽管使用CGM,仅35%试验参与者在妊娠35周达到妊娠血糖目标,对最佳产科和新生儿结局而言过晚。
  • 使用HCL(CamAPS FX系统)与TIRp提高10.5%、高血糖减少10.2%、夜间TIRp提高12.3%相关。

核心结论

  • 作者指出,能适应妊娠期胰岛素敏感性和药代动力学显著变化的HCL系统可能有助于弥合非妊娠期目标范围内时间(70-180 mg/dL)与妊娠特异目标(TIRp,63-140 mg/dL)之间的差距。
  • 女性、HCL技术与医疗团队协作实现了血糖改善,同时担忧更少、负担更轻、妊娠体验更积极。

研究设计与样本

  • 本文为2023年Norbert Freinkel奖讲座,从当代视角重新审视Freinkel关于1型糖尿病妊娠期需更积极外源性胰岛素治疗的观察。
  • 引用CONCEPTT试验数据:尽管使用CGM,仅35%试验参与者在妊娠35周达到妊娠血糖目标。

主要发现

  • CONCEPTT试验促使国际推荐为所有T1D孕妇提供CGM,以帮助其达到妊娠血糖目标并改善新生儿结局。
  • 使用HCL(CamAPS FX系统)与TIRp提高10.5%、高血糖减少10.2%、夜间TIRp提高12.3%相关。
  • 临床获益伴随妊娠期体重增长减少3.7 kg(8 lb),并在具有代表性的胰岛素泵或注射使用者人群、各试验中心及不同母亲HbA1c类别中一致实现。

关键数值与推荐

  • 非妊娠期目标范围内时间血糖目标为70-180 mg/dL,妊娠特异目标(TIRp)为63-140 mg/dL。
  • 使用HCL(CamAPS FX系统)与TIRp提高10.5%、高血糖减少10.2%、夜间TIRp提高12.3%相关,妊娠期体重增长减少3.7 kg(8 lb)。
  • 尽管使用CGM,仅35%试验参与者在妊娠35周达到妊娠血糖目标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Norbert Freinkel emphasized the need for "more aggressive therapy with exogenous insulin" during type 1 diabetes (T1D) pregnancy. Recent advances in diabetes technology, continuous glucose monitoring (CGM), and hybrid closed-loop (HCL) insulin delivery systems allow us to revisit Freinkel's observations from a contemporary perspective. The Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) led to international recommendations that CGM be offered to all pregnant women with T1D to help them meet their pregnancy glucose targets and improve neonatal outcomes. However, despite CGM use, only 35% of trial participants reached the pregnancy glucose targets by 35 weeks' gestation, which is too late for optimal obstetric and neonatal outcomes. The constant vigilance to CGM data and insulin dose adjustment, with perpetual worry about the impact of hyperglycemia on the developing fetal structures, leave many pregnant women feeling overwhelmed. HCL systems that can adapt to marked gestational changes in insulin sensitivity and pharmacokinetics may help to bridge the gap between the nonpregnant time in range glycemic targets (70-180 mg/dL) and the substantially more stringent pregnancy-specific targets (TIRp) (63-140 mg/dL) required for optimal obstetric and neonatal outcomes. Use of HCL (CamAPS FX system) was associated with a 10.5% higher TIRp, 10.2% less hyperglycemia, and 12.3% higher overnight TIRp. Clinical benefits were accompanied by 3.7 kg (8 lb) less gestational weight gain and consistently achieved across a representative patient population of insulin pump or injection users, across trial sites, and across maternal HbA1c categories. Working collaboratively, women, HCL technology, and health care teams achieved improved glycemia with less worry, less work, and more positive pregnancy experiences.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Murphy HR. A Diabetes Pregnancy Technology Roadmap: The 2023 Norbert Freinkel Award Lecture. Diabetes Care. 2024. PMID: 38394634. doi:10.2337/dci23-0067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。